FI951600A - Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine - Google Patents

Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine Download PDF

Info

Publication number
FI951600A
FI951600A FI951600A FI951600A FI951600A FI 951600 A FI951600 A FI 951600A FI 951600 A FI951600 A FI 951600A FI 951600 A FI951600 A FI 951600A FI 951600 A FI951600 A FI 951600A
Authority
FI
Finland
Prior art keywords
hiv
oligonucleotides
drug
therapeutic anti
disclosed
Prior art date
Application number
FI951600A
Other languages
English (en)
Swedish (sv)
Other versions
FI951600A0 (fi
Inventor
Sudhir Agrawal
Jin Yan Tang
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of FI951600A0 publication Critical patent/FI951600A0/fi
Publication of FI951600A publication Critical patent/FI951600A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI951600A 1992-10-05 1995-04-04 Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine FI951600A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95813592A 1992-10-05 1992-10-05
PCT/US1993/009392 WO1994008004A1 (en) 1992-10-05 1993-10-04 Therapeutic anti-hiv oligonucleotide and pharmaceutical

Publications (2)

Publication Number Publication Date
FI951600A0 FI951600A0 (fi) 1995-04-04
FI951600A true FI951600A (fi) 1995-05-10

Family

ID=25500631

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951600A FI951600A (fi) 1992-10-05 1995-04-04 Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine

Country Status (19)

Country Link
US (1) US5684147A (fi)
EP (1) EP0664833B1 (fi)
JP (1) JPH08504570A (fi)
KR (1) KR950704482A (fi)
AT (1) ATE146819T1 (fi)
AU (1) AU678415B2 (fi)
BR (1) BR9307191A (fi)
CA (1) CA2146364A1 (fi)
CZ (1) CZ85495A3 (fi)
DE (1) DE69306969T2 (fi)
DK (1) DK0664833T3 (fi)
ES (1) ES2096343T3 (fi)
FI (1) FI951600A (fi)
GR (1) GR3022315T3 (fi)
HU (1) HUT72400A (fi)
NO (1) NO951307L (fi)
NZ (1) NZ257434A (fi)
PL (1) PL308261A1 (fi)
WO (1) WO1994008004A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
DE69833438T2 (de) 1997-08-19 2006-10-26 Idera Pharmaceuticals, Inc., Cambridge Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
WO1999061056A2 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
EP1829856A3 (en) 1998-11-12 2009-02-25 Invitrogen Corporation Transfection reagents
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1422298B1 (en) * 1999-07-09 2010-01-27 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification
WO2001046448A1 (en) * 1999-12-23 2001-06-28 The Board Of Regents Of The University Of Texas System Inhibition of cellular proteases
ATE378348T1 (de) * 2000-01-14 2007-11-15 Us Health Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2002125687A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
PT1446162E (pt) 2001-08-17 2009-01-27 Coley Pharm Gmbh Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CA2630348C (en) 2005-11-17 2016-01-12 Stichting Voor De Technische Wetenschappen Inducible expression systems
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
PT2540820T (pt) 2005-12-09 2018-03-02 Academisch Medisch Centrum Bij De Univ Van Amsterdam Meios e métodos para influenciar a establidade de células produtoras de anticorpos
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
HUE033141T2 (en) 2010-12-02 2017-11-28 Aimm Therapeutics Bv Instruments and methods for producing high affinity antibodies
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
CA2958402C (en) 2013-08-26 2021-02-02 The Royal Institution For The Advancement Of Learning / Mcgill University Antisense-based small rna agents targeting the gag open reading frame of hiv-1 rna
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6747975B2 (ja) 2014-01-31 2020-08-26 アイム・セラピューティクス・べー・フェー 安定な抗体を産生するための手段及び方法
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208813T1 (de) * 1988-02-16 2001-11-15 Greatbatch Gen Aid Ltd Modifizierte zellen mit resistenz gegen retroviralinfektionen
DE68925278T2 (de) * 1988-02-26 1996-09-19 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide

Also Published As

Publication number Publication date
GR3022315T3 (en) 1997-04-30
ES2096343T3 (es) 1997-03-01
NO951307D0 (no) 1995-04-04
NO951307L (no) 1995-06-01
AU678415B2 (en) 1997-05-29
AU5402894A (en) 1994-04-26
CA2146364A1 (en) 1994-04-14
EP0664833A1 (en) 1995-08-02
HUT72400A (en) 1996-04-29
US5684147A (en) 1997-11-04
HU9500995D0 (en) 1995-06-28
NZ257434A (en) 1997-01-29
WO1994008004A1 (en) 1994-04-14
FI951600A0 (fi) 1995-04-04
DE69306969D1 (de) 1997-02-06
BR9307191A (pt) 1999-03-30
CZ85495A3 (en) 1996-03-13
KR950704482A (ko) 1995-11-20
DK0664833T3 (da) 1997-04-14
ATE146819T1 (de) 1997-01-15
EP0664833B1 (en) 1996-12-27
JPH08504570A (ja) 1996-05-21
PL308261A1 (en) 1995-07-24
DE69306969T2 (de) 1997-05-07

Similar Documents

Publication Publication Date Title
FI951600A0 (fi) Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
AU8771398A (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
ATE181960T1 (de) Gegensinnige hemmer des humanen immunmangel virus (hiv)
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
CA2165821A1 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
ATE202383T1 (de) Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
FI946201A0 (fi) Itsestabiloidut oligonukleotidit terapeuttisina aineina
DE69126311D1 (de) Therapeutische zusammensetzungen auf der basis von ribozymen
HUP0103465A2 (hu) A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
KR960704034A (ko) 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
EP0503002A4 (en) Antisense oligonucleotide inhibition of papillomavirus
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
Tonkinson et al. Antisense nucleic acids—prospects for antiviral intervention
NO965017D0 (no) Oligonukleotider med anti-cytomegalovirus aktivitet
EP0733640A4 (en) TWO-YEAR OLIGONUCLEOTIDE AND CARCINOSTATIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT
Pesce et al. Anti-gene peptide nucleic acid targeted to proviral HIV-1 DNA inhibits in vitro HIV-1 replication
Egan et al. Abasic Oligodeoxyribonucleoside Phosphorothioates as Inhibitors of the Human Immunodeficiency Virus-1 (HIV-1) Phosphorothioate Inhibition of HIV-1 Reverse Transcriptase and Interactions with Syrian Hampster Fibroblast (V79) Cells
TH23381A (th) โอลิโกนิวคลีโอไทด์สำหรับยับยั้งการแสดงลักษณะของไอโซพรีนิลโปรตีนทรานสเฟอเรส

Legal Events

Date Code Title Description
FD Application lapsed